Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the future construction of a new manufacturing plant for the active substance of low-molecular-weight heparins (“LMWH”), for which it has acquired industrial land in the Metropolitan Industry and Technology Park in Escúzar (Granada). This investment reflects ROVI’s bet on becoming, through its two flagship products, bemiparin and the enoxaparin biosimilar, one of the main European players in this market, which is worth approximately 1,500 million euros worldwide.

This operation will require ROVI to make an investment of around 24 million euros over the next three years and will double the ROVI Group’s LMWH production capacity. The investment is intended to guarantee ROVI’s future production capacity and respond to the company’s strategic growth in the LMWH field. Once again, ROVI has chosen the province of Granada and the Autonomous Region of Andalusia to continue with its expansion and development plans over the forthcoming years. In a first phase until the year 2023, the construction of the new plant will create estimated net employment of 38 jobs.

The announcement coincided with the institutional visit of the President of the Regional Government of Andalusia, Mr Juan Manuel Moreno Bonilla, to ROVI’s facilities in the Granada Health Technology Park.

As of 30 June 2019, all the EU countries where ROVI had applied for approval of the national registration of its enoxaparin biosimilar (26 countries) had approved registration and, in addition to the European countries, the company had signed marketing agreements for the product in a further 85 countries. Likewise, the international presence of bemiparin now covers 57 countries.

ROVI’s Chief Executive Officer, Juan López-Belmonte Encina, explained that, “with this new investment, ROVI guarantees the growth of its manufacturing infrastructures, which will allow us to respond to the production needs of our low-molecular-weight heparins over years to come. This is a strategic decision for the company, based on the excellent evolution of our heparin sales and the opportunity the market represents. We are confident that this decision will contribute to ROVI’s growth and we are, once again, betting on Granada and Andalusia, backed by our satisfactory experience working in the Health Technology Park over the last decade”.

ROVI in Granada

ROVI decided to invest in the Granada Health Technology Park in 2005, creating what was then the company’s first production plant outside the Madrid Region. This plant came into operation in 2009 and the active substances of the low-molecular-weight heparins that ROVI is currently marketing in more than 60 countries are manufactured there. Over this period, the company has invested more than 68 million euros in furnishing the manufacturing plant and the Granada R&D centre with the best possible resources and the initial jobs have tripled, with a current headcount of 85 highly- qualified employees (75% of whom hold degrees from Andalusian universities).

Over recent years, ROVI has reinforced its position as a company with international presence, now with a total of 1,306 employees, as a result of opening new subsidiaries in the main European markets. Direct presence in Germany, France, United Kingdom, Italy and Polonia, together with the offices in Portugal and Spain, make ROVI a benchmark pan-European company that places its trust in the Spanish industrial fabric to research and manufacture medicines that reach all corners of the world.